Sherry McCrary, APRN
Family Health · Wynne, ARNPI 1518352616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 28.4% of the total. Reporting peaked in 2021 at $498 and has fallen 94.3% since, to $28 in 2025.
Across 103 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$424
- AstraZeneca$237
- GSK$234
- Novo Nordisk$141
- Lilly USA, LLC$73
- Takeda Pharmaceuticals U.S.A., Inc.$53
- plus $333 from 15 others
What the payments were for
- Food & beverage$1,494100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
Too few family health providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $39,798 |
| JardianceEmpagliflozin | 38 | $31,916 |
| VraylarCariprazine Hcl | 20 | $28,524 |
| JanuviaSitagliptin Phosphate | 36 | $23,166 |
| TrulicityDulaglutide | 15 | $22,117 |
| MounjaroTirzepatide | 19 | $22,065 |
| EliquisApixaban | 20 | $16,212 |
| OzempicSemaglutide | 16 | $15,982 |
| FarxigaDapagliflozin Propanediol | 17 | $14,808 |
| LinzessLinaclotide | 13 | $11,125 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,931 |
| BrilintaTicagrelor | 13 | $5,657 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,067 |
| Megestrol Acetate | 14 | $1,723 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $73 | $44,18134 claims |
| GSKTrelegy Ellipta | $234 | $39,79850 claims |
| AbbVieVraylar, Linzess | $424 | $39,64833 claims |
| Boehringer IngelheimJardiance | $43 | $31,91638 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $237 | $31,46356 claims |
| Novo NordiskOzempic | $141 | $15,98216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Arkansason file to place this against a meaningful peer group, so we don't.
Other family health in Wynne
- Linda DukesHot Springs$7K
- Michelle AuldHot Springs$4K
- Jennifer JonesHot Springs$4K
- Madison BirdnoJonesboro$836
- Marie Pham-RussellFort Smith$380
- Mirenda MartinSalem$48
- Holly TolhurstJacksonville$45
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.